Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

What a 0.7% Pharma Pullback Says About the FTSE 100 After Friday's Big Rally

On Friday 30 October, the FTSE 350 pharmaceuticals sector rose more than 5%. It was the sector's biggest daily gain in about 13 months. On Monday 2 November, it fell 0.7%.

Ankur Sharma | 03 November 2026

How Smith & Nephew (LSE:SN.) Returns to the FTSE 100 Stage After August's Growth Reset

When Smith & Nephew (LSE:SN.) last spoke to the market in early August, the message was not the one investors had hoped to hear. The FTSE 100 medical technology group cut its guidance for full-year adjusted revenue growth to about 4%, down from 6%. …

Ankur Sharma | 03 November 2026

Spire Healthcare Shares Tick Up: Is the Private Hospital Operator Benefiting from NHS Waiting List Overflow?

The company operates in the Healthcare sector and is listed on the London Stock Exchange.

Divya Sood | 03 November 2026

Uniphar Plc (LSE:UPR) Holds Steady: What Are Investors Weighing?

Uniphar Plc — LSE:UPR closed unchanged on 03 November 2026, with the shares at 337p and no change on the day.

Ishan Mudgal | 03 November 2026

Avacta Group Plc (LSE:AVCT) Retreats 1.19%: What Is Behind the Pullback?

Avacta Group Plc — LSE:AVCT closed 1.19% lower on 03 November 2026, with the shares at 58p after a decrease of 0.70p on the day.

Ishan Mudgal | 03 November 2026

CelLBxHealth plc (LSE:CLBX) in AIM Spotlight: What Could Drive the Next Share-Price Move?

• The next assessment points include validation, commercial partnerships and funding, with execution andLiquiditycentral to valuation.

Ankur Sharma | 03 November 2026

Abingdon Health Plc (LSE:ABDX) in AIM Spotlight: What Could Drive the Next Share-Price Move?

• The next assessment points include order conversion and production utilisation, with execution andLiquiditycentral to valuation.

Ankur Sharma | 03 November 2026

IXICO Plc (LSE:IXI) in AIM Spotlight: What Could Drive the Next Share-Price Move?

• The next assessment points include contract awards andRevenuevisibility, with execution andLiquiditycentral to valuation.

Ankur Sharma | 03 November 2026

Fusion Antibodies Plc (LSE:FAB) in AIM Spotlight: What Could Drive the Next Share-Price Move?

• The next assessment points include service orders and cash runway, with execution andLiquiditycentral to valuation.

Ankur Sharma | 03 November 2026

ValiRx PLC (LSE:VAL) in AIM Spotlight: What Could Drive the Next Share-Price Move?

• The next assessment points include commercial partners and funding, with execution andLiquiditycentral to valuation.

Ankur Sharma | 03 November 2026
Support

Hi! How can we help you today?

Loading…